Waters Corporation has completed its $17.5 billion purchase of Becton Dickinson’s Biosciences & Diagnostic Solutions business, adding high-margin diagnostic products and technologies. The transaction diversifies Waters’ offerings beyond chromatography and mass spectrometry into broader life sciences diagnostics, positioning it for accelerated growth in medical testing markets.

Medtech industry volume increased mid-to-high-single-digit percentages while pricing remained stable, reflecting steady demand for medical devices. Underlying fundamentals support continued growth, driven by ageing populations and procedural volume increases across hospital and outpatient settings.

Sector valuation multiples have compressed as investors favor companies with embedded AI capabilities and as uncertainty from Middle East tensions pressures risk sentiment. Direct regional sales impact was limited to 2%–3%, but supply-chain concerns around semiconductors and shipping routes weigh on future cost structures.